公司資料
Cingulate Inc. 股價、新聞與催化劑
- 股票代碼:
- CING
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
5.21 USD (+2.36%)
收盤價
最後更新: 2026年8月17日
54.3M USD
市值
股價為何變動
As of Aug 17, 2026, CING closed up 2.36% at $5.21. No new same-company headline was identified in the current news window.
公司概覽
Precision Timed Release Platform
Cingulate develops next-generation medicines using its Precision Timed Release platform. The technology uses multi-core tablets to deliver several precisely timed drug releases during the day, with the goal of extending therapeutic coverage and improving adherence.
CTx-1301 ADHD Candidate
CTx-1301 is a once-daily, multi-core dexmethylphenidate hydrochloride tablet for attention-deficit/hyperactivity disorder. It is designed to provide rapid onset and efficacy throughout the active day and is being reviewed through the FDA’s 505(b)(2) pathway.
505(b)(2) Development Model
The regulatory strategy uses an established active pharmaceutical ingredient while seeking approval for a differentiated release profile and dosage form. This allows Cingulate to focus development on pharmacokinetics, duration of effect, manufacturing, and product-specific clinical performance.
Commercial Readiness
Cingulate is preparing payer access, distribution, supply chain, artificial intelligence-supported marketing technology, commercial manufacturing, and a sales organization for CTx-1301. Launch remains dependent on FDA approval.
未來催化劑
- Resubmission of the CTx-1301 NDA after completion of the requested manufacturing and CMC work.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。